Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
Emerging Treatments Could Add to Targeted Options for Psoriasis, PsA
October 31st 2022Emerging therapies for psoriasis and psoriatic arthritis (PsA) include treatments that target interleukin (IL)-23 and IL-17, which could lead to the approval of new IL-23 and IL-17 inhibitors, as well as expanding the use of currently approved options.
Read More
Study Supports Feasibility of Integrating Specialty Pharmacists in Health Systems
October 30th 2022The program, serving patients from rheumatology, dermatology, gastroenterology, allergy, and cardiology clinics, is the first of its kind within the Veterans Health Administration, researchers said.
Read More
Are NK-Cell–Based Treatments the Next Approach in Immuno-Oncology?
October 25th 2022Highlighting their ability to quickly destroy malignant cells without antigen specificity, natural killer (NK) cells have been identified as an opportunity for use, particularly in cases where T cells are not effective.
Read More
Adding Machine Learning to Longitudinal PRO Data May Prove Useful in RA
October 24th 2022In a proof-of-concept analysis, researchers show that machine learning methods paired with longitudinal patient-reported outcomes (PRO) data were able to classify subsequent rheumatoid arthritis (RA) disease activity after beginning treatment with a biologic
Read More
Identifying ASCT-Ineligible Patients Who Could Benefit From CAR T-Cell Treatment
October 22nd 2022Data suggest that the technology may be an option for patients who are ineligible for autologous stem cell transplantation (ASCT) based on certain patient characteristics, prior treatments, stem cell availability, or tumor chemosensitivity.
Read More
Patients With Asthma, Other Allergic Diseases May Have Higher Prevalence of EoE
October 18th 2022While the prevalence of eosinophilic esophagitis (EoE) is estimated to be 0.5% in the general population, a recent study found that the prevalence was as high as 16.5% in patients with allergic disease.
Read More
Level of QOL Impact of Psoriasis Does Not Appear to Be Influenced by Affected Body Region
October 18th 2022Prior to the analysis, researchers hypothesized that having localized psoriasis on more visible and/or more sensitive areas, including the face and genitals, would yield a more significant impact on quality of life.
Read More
Researchers Highlight Importance of Assessing Osteoporosis Risk Factors in RA
October 15th 2022Risk of osteoporosis and bone fractures in rheumatoid arthritis (RA) stem from disease-specific causes, disease treatment, and factors that face the general population, according to researchers, who highlighted the importance of assessing risk factors in these patients.
Read More
Researchers Explore Similarities, Differences in Guidelines for PsA Treatment
October 11th 2022In the last 2 years, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) have updated their recommendations to integrate guidance for new treatment options.
Read More
Study of IL-17A Treatment Underscores Potential of circRNA as Biomarker in Psoriasis
October 8th 2022The study, which assessed changes in circRNA and miRNA after beginning treatment with secukinumab, revealed a prompt change in circRNA abundance upon initiation of treatment and a strong correlation between circRNA and the psoriasis area and severity index.
Read More
Patients With RA Face Higher Risk of COVID-19, Hospitalization Even When Vaccinated
October 7th 2022Based on their findings, the researchers are emphasizing the importance of patients with rheumatoid arthritis (RA) receiving a booster vaccination, as well as other mitigation strategies, such as social distancing and wearing face masks.
Read More
Does Early Intervention Promote Favorable, Sustained Outcomes in Psoriasis?
October 5th 2022The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.
Read More
Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC
September 21st 2022With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.
Read More
Sustained Glucose Control Does Not Slow Decline of C-Peptide in Randomized T1D Study
September 16th 2022This randomized, multicenter study of children and adolescents with new-onset type 1 diabetes (T1D) investigated the effect on glucose control of a closed-loop system, using C-peptide levels to gauge response
Read More
Improved CPMs Needed for Guiding Methotrexate Use in RA
September 16th 2022The study analyzed 20 clinical prediction models (CPMs) for rheumatoid arthritis (RA), all of which were deemed to have a high risk of bias, leading the researchers to urge against their use to guide decision-making without addressing their limitations.
Read More
Systemic Review, Survey of Physicians Provide Insight on Targeted Therapy Use in SSc-ILD
September 13th 2022Data from a literature review of 41 studies were analyzed and subsequently leveraged to create a survey among physicians on the use of 4 targeted therapies in systemic sclerosis-interstitial lung disease (SSc-ILD).
Read More
Researchers Outline Treatment Options for Nail Psoriasis, Other Common Nail Disorders
September 9th 2022Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.
Read More
Low-Dose Secukinumab Shows Best PASI 90 in Pediatric Plaque Psoriasis
September 7th 2022This analysis of 5 studies found that, compared with placebo, all biologic regimens improved Psoriasis Area and Severity Index (PASI) 90 response—considered a gold standard goal due to its correlation with quality of life.
Read More